We further analyzed the DSS and PFI by Kaplan-Meier plotter database and found that both DSS and PFI were lower in patients with glioma with high AKR1B1 expression than in the group with low AKR1B1 expression (Figures 3(b)–3(c)). This evidence concerns the gene AKR1B1 and central nervous system cancer.